Abuse Deterrent Pharma, LLC - 09 Jun 2021 Form 4 Insider Report for ACURA PHARMACEUTICALS, INC

Role
10%+ Owner
Signature
/s/ John Schutte, Manager
Issuer symbol
N/A
Transactions as of
09 Jun 2021
Net transactions value
+$6,877,500
Form type
4
Filing time
28 Jun 2021, 11:00:40 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACUR Common Stock Conversion of derivative security $6,877,500 +42,984,375 $0.1600 42,984,375 09 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACUR Convertible Promissory Note Conversion of derivative security $0 -6,877,500 -100% $0.000000* 0 09 Jun 2021 Common Stock 42,984,375 $0.1600 Direct F1, F2
holding ACUR Warrant to Purchase Common Stock 1,782,531 09 Jun 2021 Common Stock 1,782,531 $0.5280 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The note bears interest at the rate of 7.5% per annum. On the conversion date, all principal and $877,500 of interest under the note was converted into the Issuer's common stock. For each $0.16 converted, AD Pharma received one share of common stock.
F2 This note is convertible, at the election of AD Pharma, at any time prior to repayment of the note and matures on July 1, 2023.